Analysts Offer Insights on Healthcare Companies: Nabriva (NASDAQ: NBRV), Lineage Cell Therapeutics (NYSE MKT: LCTX) and Scholar Rock Holding (NASDAQ: SRRK)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nabriva (NBRVResearch Report), Lineage Cell Therapeutics (LCTXResearch Report) and Scholar Rock Holding (SRRKResearch Report) with bullish sentiments.

Nabriva (NBRV)

In a report released today, Alan Carr from Needham maintained a Buy rating on Nabriva, with a price target of $10.00. The company’s shares closed last Monday at $1.98.

According to TipRanks.com, Carr is a 1-star analyst with an average return of -0.7% and a 42.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Lexicon Pharmaceuticals, and ACADIA Pharmaceuticals.

Nabriva has an analyst consensus of Strong Buy, with a price target consensus of $8.70.

See today’s analyst top recommended stocks >>

Lineage Cell Therapeutics (LCTX)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $4.00. The company’s shares closed last Monday at $0.72, close to its 52-week low of $0.66.

According to TipRanks.com, Nakae has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.6% and a 38.2% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Arrowhead Research, and Arbutus Biopharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Cell Therapeutics with a $3.67 average price target.

Scholar Rock Holding (SRRK)

Cowen & Co. analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding today. The company’s shares closed last Monday at $8.73, close to its 52-week low of $8.05.

According to TipRanks.com, Frahm is a 1-star analyst with an average return of -0.6% and a 52.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Allogene Therapeutics, and Applied Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Scholar Rock Holding.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.